Skip to content

Eli Lilly LLY Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin82.8%-0.2pp83%0.0pp83%+0.4pp82.6%+0.9pp81.7%+0.4pp
Net margin35%+3.3pp31.7%+0.7pp31%+5.1pp25.9%+3.2pp22.7%-0.8pp
EBITDA margin45.9%+3.4pp42.5%+1.5pp41.1%+5.9pp35.2%+3.7pp31.5%-0.6pp
Free cash flow margin16.4%+2.6pp13.8%-1.8pp15.6%
Returns
Return on equity107.6%+6.5pp101.2%+4.3pp96.8%+10.1pp86.7%+9.0pp77.7%-6.8pp
Return on assets24.5%+3.0pp21.6%+2.3pp19.3%+3.4pp16%+1.5pp14.5%-0.4pp
Return on invested capital42%+3.7pp38.3%+0.9pp37.4%+8.0pp29.4%+4.0pp25.3%-1.1pp
Efficiency
Asset turnover0.7×0.0×0.7×+0.1×0.6×0.0×0.6×0.0×0.6×0.0×
Inventory turnover0.0×0.0×0.0×1.1×-0.1×1.2×-0.1×
Liquidity
Current ratio1.5×-0.1×1.6×0.0×1.5×+0.3×1.3×-0.1×1.4×+0.2×
Quick ratio1.1×-0.1×1.2×-0.1×1.2×+0.2×-0.1×1.1×+0.2×
Cash ratio0.1×-0.1×0.2×0.0×0.2×+0.2×0.1×0.0×0.1×0.0×
Leverage
Debt-to-equity1.4×-0.2×1.6×-0.2×1.8×-0.4×2.2×-0.3×2.4×0.0×
Debt-to-assets0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×
Net debt / EBITDA1.1×-0.1×1.3×-0.1×1.3×-0.6×1.9×-0.3×2.3×+0.1×
Per Share
Book value per share$34.82+18.0%$29.51+11.5%$26.47+30.4%$20.31+16.0%$17.50+10.9%
Valuation
Market capitalization$821.68B-14.6%$961.86B+40.6%$684B-2.1%$698.51B-5.8%$741.66B+6.8%
Enterprise value$859.77B-13.8%$997.32B+39.2%$716.71B-2.5%$735.04B-5.4%$777.08B+7.1%
Price / earnings32.5×-14.1×46.6×+9.5×37.1×-13.5×50.6×-16.2×66.8×+1.2×
Price / sales11.4×-3.4×14.8×+3.2×11.5×-1.6×13.1×-2.0×15.1×-0.3×
Price / book26.3×-9.9×36.2×+7.5×28.7×-9.5×38.2×-8.8×47×-1.6×
EV / EBITDA25.9×-10.0×36×+6.6×29.4×-9.8×39.2×-11.2×50.4×+0.1×
EV / sales11.9×-3.4×15.3×+3.2×12.1×-1.7×13.8×-2.1×15.9×-0.3×
Free cash flow yield1.4%+0.5pp0.9%-0.4pp1.4%
Earnings yield3.1%+0.9pp2.1%-0.5pp2.7%+0.7pp2%+0.5pp1.5%0.0pp
Dividend yield0.7%+0.1pp0.6%-0.2pp0.8%0.0pp0.7%+0.1pp0.7%0.0pp
PEG ratio0.3×-0.2×0.5×+0.2×0.3×-0.3×0.6×-0.2×0.8×+0.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Eli Lilly's ratios come from?
Every ratio is computed from Eli Lilly's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.